Medical progress: Acromegaly

被引：842
作者：
Melmed, Shlomo [1 ]
机构：
[1] Univ Calif Los Angeles, Cedars Sinai Med Ctr, David Geffen Sch Med, Dept Med, Los Angeles, CA 90048 USA
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2006年 / 355卷 / 24期
关键词：
D O I：
10.1056/NEJMra062453
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2558 / 2573
页数：16
相关论文
共 103 条
[1]   The 2004 World Health Organization classification of pituitary tumors: What is new? [J].
Al-Shraim, M ;
Asa, SL .
ACTA NEUROPATHOLOGICA, 2006, 111 (01) :1-7
[2]   IDENTIFICATION OF JAK2 AS A GROWTH-HORMONE RECEPTOR-ASSOCIATED TYROSINE KINASE [J].
ARGETSINGER, LS ;
CAMPBELL, GS ;
YANG, XN ;
WITTHUHN, BA ;
SILVENNOINEN, O ;
IHLE, JN ;
CARTERSU, C .
CELL, 1993, 74 (02) :237-244
[3]   Genetics and proteomics of pituitary tumors [J].
Sylvia L. Asa ;
Shereen Ezzat .
Endocrine, 2005, 28 (1) :43-47
[4]   Lanreotide 60 mg, a new long-acting formulation: Effectiveness in the chronic treatment of acromegaly [J].
Attanasio, R ;
Baldelli, R ;
Pivonello, R ;
Grottoli, S ;
Bocca, L ;
Gasco, V ;
Giusti, M ;
Tamburrano, G ;
Colao, A ;
Cozzi, R .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (11) :5258-5265
[5]   Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly [J].
Ayuk, J ;
Clayton, RN ;
Holder, G ;
Sheppard, MC ;
Stewart, PM ;
Bates, AS .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (04) :1613-1617
[6]   Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant [J].
Barkan, AL ;
Burman, P ;
Clemmons, DR ;
Drake, WM ;
Gagel, RF ;
Harris, PE ;
Trainer, PJ ;
van der Lely, AJ ;
Vance, ML .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (10) :5684-5691
[7]   Hormonal and metabolic effects of radiotherapy in acromegaly: Long-term results in 128 patients followed in a single center [J].
Barrande, G ;
Pittino-Lungo, M ;
Coste, J ;
Ponvert, D ;
Bertagna, X ;
Luton, JP ;
Bertherat, J .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (10) :3779-3785
[8]   The role of pharmacotherapy in perioperative management of patients with acromegaly [J].
Ben-Shlomo, A ;
Melmed, S .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (03) :963-968
[9]   Acromegaly caused by secretion of growth hormone by a non-Hodgkin's lymphoma. [J].
Beuschlein, F ;
Strasburger, CJ ;
Siegerstetter, V ;
Moradpour, D ;
Lichter, P ;
Bidlingmaier, M ;
Blum, HE ;
Reincke, M .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (25) :1871-1876
[10]   Clinical review: The antitumoral effects of somatostatin analog therapy in acromegaly [J].
Bevan, JS .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (03) :1856-1863
12345678910